Cost-Effectiveness and Population Impact of Statins for Primary Prevention in Adults Aged 75 Years or Older in the United States (Odden and colleaguesAnnals of Internal Medicine) and accompanying editorial, Cost-Effectiveness of Statins in Older Adults: Further Evidence That Less Is More (Rich)

From the primary prevention study of U.S. adults aged 75-94 years, the authors conclude: “At effectiveness similar to that in trials, statins are projected to be cost-effective for primary prevention; however, even a small increase in geriatric-specific adverse effects could offset the cardiovascular benefit.” From the editorial: “The key take-home message from this study is that despite low cost and high potential benefit, even very modest adverse events attributable to statins tip the balance in the direction of harm.”

Leave a comment